Global Acute Myeloid Leukaemia Market Forecast 2018-2028 - Visiongain Report

LONDON, September 25, 2018 /PRNewswire/ --

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib 

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 135-page report you will receive 92 charts- all unavailable elsewhere.

The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Acute Myeloid Leukaemia Market from 2018-2028

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Visiongain's study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Buy our report today Global Acute Myeloid Leukaemia Market Forecast 2018-2028: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-2018-2028/

AbbVie
Agios Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Amgen
Animas Corporation
Astex
B. Braun Melsungen AG
Baxter, Becton, Dickinson and Company (BD)
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb Company (Bristol-Myers)
Celator Pharmaceuticals, Inc.
Celgene
Clavis Pharma ASA (Clavis Pharma)
Cyclacel
Daiichi Pharmaceutical
Daiichi Sankyo
Eisai Co., Ltd. (Eisai)
F. Hoffmann-La Roche Ltd. (Roche)
Fresenius SE & Co. KGaA
GlaxoSmithKline plc (GSK)
GLOBOCAN
Hospira
Medtronic
Moog Inc.
NeoMed
Norsk Hydro
Novartis
Onyx Pharmaceuticals
Sankyo
Seattle Genetics
Smiths Group Plc.,
Sunesis Pharmaceuticals, Inc. (Sunesis)
TEVA Pharmaceutical Industries Limited (TEVA)

List of Organizations Mentioned in the Report
American Cancer Organization
Baylor Scott and White Research Institute
Benaroya Research Institute at Virginia Mason
Beth Israel Deaconess Medical Center
Breslin Cancer Center
Center for Blood Disorders and Stem Cell Transplantation
Charles A. Sammons Cancer Center
Columbia University Medical
Dana Farber Cancer Institute
Duke Cancer Center
European Commission
Fred Hutchinson Cancer Research Center
Health Canada
Herbert Irving Comprehensive Cancer Center
Institute of Hematology & Blood Diseases Hospital,Tianjin
James Graham Brown Cancer Center
Legacy Emanuel Hospital & Health Center
Mary Babb Randolph Cancer Center
Massachusetts general Hospital
Mayo Clinic
MD Anderson Cancer Center
Medical College of Wisconsin Cancer Center
Medizinische Klinik und Poliklinik I
Memorial Sloan Kettering Cancer Center
Michigan State University
Nantes University Hospital
National Cancer Institute
New Jersey Hematology Oncology Associates
Northwestern University
Ochsner Medical Center
Penn State Hershey Cancer Institute-Clinical Trials Office
Perelman Center for Advanced Medicine
Princess Margaret Hospital
St. Francis Cancer Center
St. Joseph Mercy Hospital
St. Vincent's Comprehensive Cancer Center
Swedish Cancer Institute
The Gayle and Tom Benson Cancer Center
The University of Hong Kong
The University of Iowa
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
U.S. Food and Drug Administration (FDA)
UCLA Medical Center, Division of Hematology/Oncology
University Hospital, Caen
University of Kansas Cancer Center
University of Kansas Medical Center Research Institute
University of Kentucky
University of Louisville
University of Michigan Health System
University of Pennsylvania
University of Texas M.D. Anderson Cancer Center
VA Caribbean Healthcare System
Weill Cornell Medical College
Weill Medical College of Cornell University
West Virginia University
World Health Organization (WHO)

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com